Acorda Therapeutics (ACOR) Tops Q2 EPS by 7c
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of $0.19, $0.07 better than the analyst estimate of $0.12. Revenue for the quarter came in at $65.28 million versus the consensus estimate of $66.29 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
